| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2174/1566524033479654 |
| P698 | PubMed publication ID | 12942995 |
| P50 | author | Brian Dean | Q37838392 |
| P2093 | author name string | F P Bymaster | |
| E Scarr | |||
| P433 | issue | 5 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 419-426 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Current Molecular Medicine | Q5195065 |
| P1476 | title | Muscarinic receptors in schizophrenia | |
| P478 | volume | 3 |
| Q37212798 | A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia |
| Q33770771 | A new approach for structure analysis of two-dimensional membrane protein crystals using X-ray powder diffraction data. |
| Q30491322 | Application of electroencephalography to the study of cognitive and brain functions in schizophrenia. |
| Q34006864 | Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles |
| Q24645178 | Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 |
| Q43198404 | Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice |
| Q46572556 | Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults |
| Q24654110 | Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects |
| Q41577891 | Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex |
| Q41192413 | Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. |
| Q55710562 | Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity. |
| Q34163202 | Inhibition of post-synaptic Kv7/KCNQ/M channels facilitates long-term potentiation in the hippocampus |
| Q37506679 | Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. |
| Q26774667 | KCNQ potassium channels in sensory system and neural circuits |
| Q44987786 | M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia |
| Q34843883 | Newer molecules in the treatment of schizophrenia: A clinical update |
| Q37064021 | Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings |
| Q36686912 | Rat modeling for GABA defects in schizophrenia |
| Q33948009 | Regulation of synaptic plasticity in a schizophrenia model |
| Q43260110 | Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors |
| Q30457634 | Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice |
| Q37356496 | Role of the cholinergic system in the pathology and treatment of schizophrenia. |
| Q46375972 | The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? |
| Q46440592 | Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs |
| Q92717037 | Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia |
Search more.